A vaccine developed using artificial intelligence has successfully completed its first human clinical trial. Researchers from the Universities of Cambridge and Southampton created a 'universal vaccine' aimed at providing protection against multiple Sarbeco coronaviruses, including SARS-CoV-2, which caused the COVID-19 pandemic. The trial involved 39 healthy volunteers and demonstrated safety as well as an immune response. This vaccine was designed entirely through computer simulations, marking a significant milestone in vaccine development.
The vaccine was administered using a micro-fluid jet, which delivers the immunization through the skin without the need for needles, potentially facilitating faster mass vaccinations. Professor Saul Faust, the trial’s chief investigator, noted that traditional vaccines often lag behind due to the rapid evolution of viruses, making this new approach crucial for future pandemic preparedness.
While the results are promising, experts have raised concerns regarding the use of AI in medicine, particularly regarding potential biases in data and the implications of AI-generated information. The researchers emphasized the need for larger trials with more diverse populations to validate their findings, which were published in the Journal of Infection.